The extensive focus on the discovery and preclinical evaluation of small molecule IL-6 inhibitors in recent years [153,154,155] holds promise for the future of small molecule-based IL-6/IL-6R inhibition in GBM treatment. The gene discussed is IL6; the disease is glioblastoma.